Journal
JOURNAL OF NEUROSCIENCE
Volume 37, Issue 30, Pages 7079-7095Publisher
SOC NEUROSCIENCE
DOI: 10.1523/JNEUROSCI.0931-17.2017
Keywords
axon regeneration; drug discovery; drug target; kinase; S6K; spinal cord injury
Categories
Funding
- Department of Defense [W81XWH-13-1-077, CDMRP W81XWH-12-1-0562]
- National Institutes of Health [HD057632, NS059622]
- U.S. Department of Veterans Affairs Merit Review Award [I01 BX002356]
- Craig H. Neilsen Foundation [296749]
Ask authors/readers for more resources
The mammalian target of Rapamycin (mTOR) positively regulates axon growth in the mammalian central nervous system (CNS). Though axon regeneration and functional recovery from CNS injuries are typically limited, knockdown or deletion of PTEN, a negative regulator of mTOR, increases mTOR activity and induces robust axon growth and regeneration. It has been suggested that inhibition of S6 Kinase 1 (S6K1, gene symbol: RPS6KB1), a prominent mTOR target, would blunt mTOR's positive effect on axon growth. In contrast to this expectation, we demonstrate that inhibition of S6K1 in CNS neurons promotes neurite outgrowth in vitro by 2-3 fold. Biochemical analysis revealed that an mTOR-dependent induction of PI3K signaling is involved in mediating this effect of S6K1 inhibition. Importantly, treating female mice in vivo with PF-4708671, a selective S6K1 inhibitor, stimulated corticospinal tract (CST) regeneration across a dorsal spinal hemisection between the cervical 5 and 6 cord segments (C5/C6), increasing axon counts for at least 3 mm beyond the injury site at 8 weeks after injury. Concomitantly, treatment with PF-4708671 produced significant locomotor recovery. Pharmacological targeting of S6K1 may therefore constitute an attractive strategy for promoting axon regeneration following CNS injury, especially given that S6K1 inhibitors are being assessed in clinical trials for non-oncological indications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available